Evidence for a biochemical lesion in depression

Journal of Clinical Psychiatry

Volumn 61, Issue SUPPL. 6, 2000, Pages 12-17

  Leonard, Brian E ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; CLONIDINE; DESIPRAMINE; FENFLURAMINE; FLUOXETINE; IMIPRAMINE; MONOAMINE; NORADRENALIN; REBOXETINE; SEROTONIN; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRITIUM;

CONFERENCE PAPER; DEPRESSION; HUMAN; MENTAL DISEASE; NEUROTRANSMISSION; NORADRENERGIC SYSTEM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; SEROTONINERGIC SYSTEM;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; HUMANS; MODELS, BIOLOGICAL; NOREPINEPHRINE; RECEPTORS, BIOGENIC AMINE; SEROTONIN;

EID: 0034100196     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (84)

1. Potter WZ, Muscettola G, Goodwill FK. Sources of variance in clinical studies in MHPG. In: Maas JW, ed. MHPG: Basic Mechanisms and Basic Psychopathology. New York, NY: Academic Press; 1983:145-165
2. Maas J, Fawcett J, Dekirmenjian H. Catecholamine metabolism, depressive illness and drug responses. Arch Gen Psychiatry 1972;26:252-262
3. Schatzberg AF, Samson JA, Bloomingdale KL, et al. Toward a biochemical classification of depressive disorders, X: urinary catecholamines, their metabolites and D-type scores in subgroups of depressive disorders. Arch Gen Psychiatry 1989;46:260-268
4. Schildkraut JJ, Orsulak PJ, Schatzberg AF, et al. Toward a biochemical classification of depressive disorders, I: differences in urinary excretion of MHPG and other catecholamine metabolites in clinically defined subtypes of depressions. Arch Gen Psychiatry 1978;35:1427-1433
5. Muscettola G, Potter WZ, Pickar D, et al. Urinary 3-methoxy-4-hydroxyphenyl-glycol and major affective disorders. Arch Gen Psychiatry 1984;41: 337-342
6. Potter WZ, Scheinin M, Goalden RN, et al. Selective antidepressam and cerebrospinal fluid: lack of specificity on noradrenaline and serotonin metabolism. Arch Gen Psychiatry 1985;42:1171-1177
7. Post RM, Lake CR, Jimerson DC, et al. Cerebrospinal fluid norepinephrine in affective illness. Am J Psychiatry 1978;135:907-912
8. Christensen NJ, Vestergaard P, Sørensen T, et al. Cerebrospinal fluid adrenaline and noradrenaline in depressed patients. Acta Psychiatr Scand 1980;61:178-182
9. Roy A, Pickar D, Linnoila M, et al. Cerebrospinal fluid monoamine and monoamine metabolite concentrations in melancholia. Psychiatry Res 1985;15:281-292
10. Roy A, De Jong J, Linnoila M. Cerebrospinal fluid monoamine metabolites and suicidal behavior in depressed patients. Arch Gen Psychiatry 1989;46: 609-612
11. Nordström P. Åsberg M. Suicide risk and serotonin. Int Clin Psychopharmacol 1992;6:12-21
12. Åsberg M, Thorèn P, Träskman L, et al. "Serotonin depression": a biochemical subgroup within the affective disorders? Science 1976;191:478-480
13. Peabody CA, Faull KF, King RJ, et al. CSF amine metabolites in depression. Psychiatry Res 1987;21:1-7
14. Gibbons RD, Davis JM. Consistent evidence for a biological subtype of depression characterised by low CSF monoamine levels. Acta Psychiatr Scand 1984;74:8-12
15. Miller HL, Delgado PL, Salomon RM, et al. Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression. Arch Gen Psychiatry 1996;53:117-128
16. Delgado PL, Price LH, Miller HL, et al. Serotonin and the neurobiology of depression: effects of tryptophan depletion in drug-free depressed patients. Arch Gen Psychiatry 1994;51:865-874
17. Delgado PL, Moreno FA, Potter R, et al. Norepinephrine and serotonin in antidepressant action: evidence from neurotransmitter depletion studies. In: Briley M, Montgomery SA, eds. Antidepressant Therapy at the Dawn of the Third Millennium. London, UK: Martin Dunitz Ltd; 1997;141-163
18. Melia KR, Rasmussen K, Terwilliger RZ, et al. Coordinate regulation of the cyclic AMP system with firing rate and expression of tyrosine hydroxylase in the rat locus coeruleus: effects of chronic stress and drug treatment. J Neurochem 1992;58:494-502
19. Brady LS. Stress, antidepressant drugs and the locus coeruleus. Brain Res Bull 1994;35:545-556
20. Biegon A, Fieldust S. Reduced tyrosine hydroxylase immunoreactivity in locus coeruleus of suicide victims. Synapse 1992;10:79-82
21. Ordway GA, Smith KS, Haycock JW. Elevated tyrosine hydroxylase in the locus coeruleus of suicide victims. J Neurochem 1994;62:680-685
22. Valentino RJ, Curtis AL, Parris DG, et al. Antidepressant actions on brain noradrenergic neurons. J Pharmacol Exp Ther 1990;253:833-840
23. Leonard BE. Noradrenaline in basic models of depression. Eur Neuropsychopharmacol 1997;7(suppl 1):S11-S16
24. Gottfries CG, Oreland L, Wiberg A, et al. Lowered monoamine oxidase activity in the brains from alcoholic suicides. J Neurochem 1975;25: 667-673
25. Lesch K-P, Wolozin BL, Murphy DL, et al. Primary structure of the human platelet serotonin uptake site: identity with the brain serotonin transporter. J Neurochem 1993;60:2319-2322
26. Briley MS, Langer SZ, Raisman R, et al. Tritiated imipramine binding sites are decreased in platelets of untreated depressed patients. Science 1980; 209:303-305
27. Perry EK, Marshall EF, Blessed G, et al. Decreased imipramine binding in the brains of patients with depressive illness. Br J Psychiatry 1983;142: 188-192
28. Owens MJ, Nemeroff CB. Role of serotonin in the pathophysiology of depression: focus on the serotonin receptor. Clin Chem 1994;40:288-295
29. Cheetham SC, Katona CLE, Horton RW. Post-mortem studies of neurotransmitter biochemistry in depression and suicide. In: Horton RW, Katona CLE, eds. Biological Aspects of Affective Disorders. London, UK: Academic Press; 1991:191-221
30. Freeman AM, Stankovic SMI, Bradley R, et al. Tritiated platelet imipramine binding and treatment response in depressed outpatients. Depression 1993;1:20-23
31. Healy D, Carney PA, Leonard BE. Monoamine-related markers of depression: changes following treatment. J Psychiatr Res 1983;17:251-260
32. Healy D, Carney PA, O'Halloran A, et al. Peripheral adrenoceptors and serotonin receptors in depression. J Affect Disord 1985;9:285-296
33. Malison RT, Price LH, Berman R, et al. Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 betacarbomethoxy-3-beta-(4-iodophelyl)tropane and single photon emission computed tomography. Biol Psychiatry 1998;44:1090-1098
34. Lesch K-P, Aulakh CS, Wolozin BL, et al. Regional brain expression of serotonin transporter mRNA and its regulation by reuptake inhibiting antidepressants. Mol Brain Res 1993;17:31-35
35. Heils A, Teufel A, Petri S, et al. Allelic variation of human serotonin transporter gene expression. J Neurochem 1996;66:2621-2624
36. Lesch K-P, Bengel D, Heils A, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996;274:1527-1531
37. 3H)desmethylimipramine binding in the human brain postmortem. Brain Res 1988;456:120-126
38. Klimek V, Stockmeier C, Overholser J, et al. Reduced levels of norepinephrine transporters in the locus coeruleus in major depression. J Neurosci 1997;17:8451-8458
39. Hadley D, Hoff M, Holik J, et al. Manic-depression and the norepinephrine transporter gene. Hum Hered 1995;45:165-168
40. 1 binding sites in depressed suicides. Psychopharmacology (Berl) 1990;102:544-548
41. Stockmeier CA, Shapiro LA, Dilley GE, et al. Increase in serotonin 1A autoreceptors in the midbrain of suicide victims with major depression: postmortem evidence for decreased serotonin activity. J Neurosci 1998;18: 7394-7401
42. 1A receptor binding sites in post-mortem brain samples from depressed suicides and controls. J Affect Disord 1997;42:199-207
43. Stockmeier CA, Dilley GE, Shapiro LA, et al. Serotonin receptors in suicide victims with major depression. Neuropsychopharmacology 1997;16: 162-173
44. Stanley M, Mann JJ. Increased serotonin-2 binding sites in frontal cortex of suicide victims. Lancet 1983;1:214-216
45. 2 binding sites in the frontal cortex of suicide victims and control subjects. Am J Psychiatry 1989;146:730-736
46. Crow TJ, Cross AJ, Cooper SJ, et al. Neurotransmitter receptors and monoamine metabolites in the brains of patients with Alzheimer-type dementia and depression, and suicides. Neuropharmacology 1984;23:1561-1569
47. Owen F, Chambers DR, Cooper SJ, et al. Serotonergic mechanisms of brains in suicide victims. Brain Res 1986;362:185-188
48. 2 receptor imaging in major depression: focal changes in orbito-insular cortex. Br J Psychiatry 1997;171:444-448
49. Butler J, Leonard BE. The platelet serotonin system in depression and following sertraline treatment. Int Clin Psychopharmacol 1988;3:343-347
50. 2A receptors unchanged by antidepressant treatment. Psychiatry Res 1997;66:73-85
51. Bakish D, Cavazzoni P, Chudzik J, et al. Effects of selective serotonin reuptake inhibitors on platelet serotonin parameters in major depressive disorder. Biol Psychiatry 1997;41:184-190
52. Graeff FG. Serotonergic systems. Psychiatr Clin North Am 1997;20: 723-739
53. Deakin JFW, Pennell I, Upadhyaya AJ, et al. A neuroendocrine study of 5-HT function in depression: evidence for biological mechanisms of endogenous and psychosocial causation. Psychopharmacology 1990;101: 85-92
54. Golden RN, Hsiao JK, Lane E, et al. Abnormal neuroendocrine responsivity to acute i.v. clomipramine challenge in depressed patients. Psychiatry Res 1990;31:39-47
55. Mitchell P, Smythe G. Hormonal responses to fenfluramine in depressed and control subjects. J Affect Disord 1990;19:43-51
56. Anand A, Charney DS, Delgado PL, et al. Neuroendocrine and behavioral responses to intravenous m-chlorophenylpiperazine (mCPP) in depressed patients and healthy comparison subjects. Am J Psychiatry 1994;151: 1626-1630
57. 2-Adrenoceptors in the brain of suicide victims: increased receptor density associated with major depression. Biol Psychiatry 1992;31:471-490
58. 2A-adrenoceptor agonist binding sites in brains of depressed suicide victims. J Neurochem 1998;70:1114-1123
59. Bricca G, Doontenwill M, Molines A, et al. The imidazoline preferring receptor: binding studies in bovine rat and human brain-stem. Eur J Pharmacol 1989;162:1-9
60. 3H]rauwolscine. Brain Res 1991;566:13-20
61. 2-receptors after chronic desipramine treatment. Life Sci 1980;27: 1863-1867
62. Charney DS, Heninger GR, Sternberg D, et al. Presynaptic adrenergic receptor sensitivity in depression: the effect of long-term desipramine treatment. Arch Gen Psychiatry 1981;38:1334-1340
63. 2-adrenergic receptors in major depressive disorder: binding of tritiated clonidine before and after tricyclic antidepressant drug treatment. Arch Gen Psychiatry 1981;38:1327-1333
64. 2-Adrenoceptor levels on platelets of patients with major depressive disorders. Psychiatry Res 1986;18:321-331
65. 3H-imipramine binding in elderly depressed patients. Life Sci 1987;40:2137-2143
66. 2-adrenergic receptors in depressed patients and healthy volunteers: the effects of desipramine. Pharmacopsychiatry 1992;25:199-206
67. Siever LJ, Coccaro EF, Benjamin E, et al. Adrenergic and serotonergic receptor responsiveness in depression. Ciba Found Symp 1986;123:148-163
68. 2-adrenergic function and suicidal behavior in depressed patients. Psychiatry Res 1993;52:115-123
69. Karege F, Bovier P, Hilleret H, et al. Lack of effect of anxiety on total plasma MHPG in cepressed patients. J Affect Disord 1993;28:211-217
70. 2-Adrenoceptor mediated inhibition of platelet adenylate cyclase and induction of aggregation in major depression. Arch Gen Psychiatry 1990;47:125-132
71. Biegon A, Israeli M. Regionally selective increases in beta-adrenergic receptor density in the brains of suicide victims. Brain Res 1988;442: 199-203
72. Mann JJ, Stanley M, McBride PA, et al. Increased serotonin-2 and beta-adrenergic receptor binding in the frontal cortices of suicide victims. Arch Gen Psychiatry 1986;43:954-959
73. De Paermentier F, Cheetham SC, Crompton MR, et al. Brain beta-adrenoceptor binding sites in antidepressant-free depressed suicide victims. Brain Res 1990;525:71-77
74. Vetulani J, Sulser F. Action of various antidepressant treatments reduces reactivity of noradrenergic cyclic AMP-generation system in limbic forebrain. Nature 1975;257:495-496
75. Heal DJ, Bristow LM, Hurst EM, et al. Sex-related differences in central adrenergic function and responsiveness to repeated administration of desipramine and electroconvulsive shock. Br J Pharmacol 1989;97: 111-118
76. Butler J, Leonard BE. Post-partum depression and the effect of nomifensine treatment. Int Clin Psychopharmacol 1986;1:244-252
77. Extein J, Tallman J, Smith CC, et al. Changes in lymphocyte beta-adrenergic receptors in depression and mania. Psychiatry Res 1979;1:192-197
78. Mann JJ, Brown RP, Halper JP, et al. Reduced sensitivity of lymphocyte beta-adrenergic receptors in patients with endogenous depression and psychomotor agitation. N Engl J Med 1985;313:715-720
79. Perez J, Tinelli D, Bianchi E, et al. cAMP binding proteins in the rat cerebral cortex after administration of selective 5-HT and NA reuptake blockers with antidepressant activity. Neuropsychopharmacology 1991;4:57-64
80. Racagni G, Brunello N, Tinelli D, et al. New biochemical hypotheses on the mechanism of action of antidepressant drugs: cAMP-dependent phosphorylation system. Pharmacopsychiatry 1992;25:51-55
81. 2+/calmodulindependent protein kinase, II: autophosphorylation and activity increase in the hippocampus after long-term blockade of serotonin reuptake. Mol Pharmacol 1995;48:623-629
82. Brunello N, Racagni G. Rationale for the development of noradrenaline reuptake inhibitors. Hum Psychopharmacol 1998;13:S13-S19
83. Manji HK. G proteins: implications for psychiatry. Am J Psychiatry 1992; 149:746-760
84. Schatzberg AF. Noradrenergic versus serotonergic antidepressants: predictors of treatment response. J Clin Psychiatry 1998;59(suppl 14):15-18